Glepaglutide increases Intestinal Absorptions in Short Bowel Syndrome Patients
Background: Glepaglutide is a long-acting glucagon-like peptide-2 analog, which reduces parenteral support (PS) requirements in adult short bowel syndrome (SBS) patients with intestinal failure (Jeppesen PB et al. Gastroenterology 2024). We here report the efficacy of glepaglutide therapy on intestinal absorptions in SBS patients.
Authors
- Lise Soldbro
- Ismail Pinar (ORCID: https://orcid.org/0000-0002-8713-4575)
- Mark Berner Hansen (ORCID: https://orcid.org/0009-0003-7487-5141)
- Thor SS Nielsen
- Palle Bekker Jeppesen (ORCID: https://orcid.org/0000-0001-9680-6938)
Institutions
- Bispebjerg Hospital (DK)
- Rigshospitalet (DK)
- Zealand Pharma (Denmark) (DK)
Publication Details
- Journal
- Intestinal failure.
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1016/j.intf.2025.100087
- Primary Topic
- Clinical Nutrition and Gastroenterology
- Type
- article
- Field-Weighted Citation Impact
- 0.00